Publication

Article

Pharmacy Times

November 2024
Volume90
Issue 11

November 2024 Product News

Key Takeaways

  • Cologuard Plus, approved for colorectal cancer screening, showed 93.9% sensitivity and 90.6% specificity in the BLUE-C trial.
  • Dupilumab, approved for COPD with eosinophilic phenotype, reduced exacerbations and improved lung function in phase 3 trials.
SHOW MORE

RX Products

Cologuard Plus

From: Exact Sciences Corp

The FDA recently approved Cologuard Plus, a multitarget stool DNA test that can screen adults aged 45 years and older who are at average risk for colorectal cancer. The approval was based on results from the BLUE-C trial (NCT04144738), which showed 93.9% sensitivity for colorectal cancer and 43.4% sensitivity for advanced precancerous lesions, as well as 90.6% specificity for advanced neoplasia. These results also suggest that Cologuard Plus demonstrates significant superiority over an independent fecal immunochemical test for overall colorectal cancer sensitivity, treatable-stage colorectal cancer sensitivity, and advanced precancerous lesion sensitivity.

For more information: exactsciences.com

Dupilumab (Dupixent)

From: Regeneron Pharmaceuticals, Inc, and Sanofi Aventis US LLC

The FDA approved dupilumab as an add-on maintenance therapy for adult patients who have inadequately controlled chronic obstructive pulmonary disease and an eosinophilic phenotype. The approval is based on data from 2 phase 3 trials—BOREAS (NCT03930732) and NOTUS (NCT04456673)—in which dupilumab achieved a significant reduction in exacerbations while improving lung function and health-related quality of life compared with placebo. The most common adverse events across both trials, and more common in those receiving dupilumab, were viral infection, headache, nasopharyngitis, back pain, diarrhea, arthralgia, urinary tract infection, local administration reaction, rhinitis, eosinophilia, toothache, and gastritis.

For more information: dupixenthcp.com

OTC Product

Fertility Support

From: Ritual

Ritual has released its 3-in-1 Fertility Support supplement designed to support conception outcomes. The product contains 200 mg of coenzyme Q10, which plays a role in supporting follicular health and cellular energy production. The supplement also includes 1.2 g of N-acetyl cysteine and 4 g of myo-inositol, which boosts ovarian health and ovulation. Fertility Support was created in collaboration with obstetricians and gynecologists, fertility specialists, and medical practitioners. The lemon-flavored drink mix should be taken twice daily, once in the morning and once at night.

For more information: ritual.com

Generic Product

Amantadine Hydrochloride Extended-Release Capsules 68.5 mg

Compare with: Gocovri

From: Zydus Pharmaceuticals Inc

Amantadine, an antiviral medication used to treat Parkinson disease by blocking the actions of viruses in the body, recently received generic approval. The drug is also used to prevent influenza A in adults and adolescents but has only displayed effectiveness for certain strains of the virus. Amantadine is available in tablets, capsules, and as an oral solution. Individuals should take the medicine as prescribed by their health care provider; tablets and capsules should be taken whole, and the oral solution should be measured appropriately with the provided dosing syringe. Common adverse events when taking amantadine include dizziness, dry mouth, swelling in legs or feet, nausea, constipation, and insomnia.

For more information: zydususa.com

Related Videos
Psychiatrist talking a patient about their mental health
Heart with stethoscope | Image Credit: © DARIKA - stock.adobe.com
Senior Doctor is examining An Asian patient.
Healthcare, pharmacist and woman at counter with medicine or prescription drugs sales at drug store.
Image Credit: © Birdland - stock.adobe.com